Swiss Glucose-Monitoring Startup Liom Raises €13.9 Million In Series A Round

The round was led by existing investors, with new participation from Red Bull Ventures, Marc Maurer (former co-CEO of On Running), Melih Odemis (former co-founder and CTO of Yemeksepeti), and Alejo Costa Ribalta (partner at CRB Health Tech and former Philips/GE Healthcare executive).

This brings Liom’s total Series A funding to €40.8 million (CHF 38 million) and total funding to date to €67.6 million (CHF 63 million).

“Now, we can also be sure that we’ve not only proven the method, but we had the right team and the right amount of luck to generate the required breakthrough innovations in order to bring our platform into a wearable-fitting form-factor,” says Leo Grünstein, founder and CEO of Liom.

In 2025 European HealthTech startups specializing in wearables, biosensing and preventive care have attracted significant venture capital reflecting growing investor confidence in technologies that provide continuous health insights beyond traditional clinical settings.

Read Also - StretchSense Raises $2.3 Million For Wearable Data Capture Gloves

For instance, Sava Technologies Ltd., a London-based MedTech firm developing real-time molecular wearable sensors raised €16.6 million in Series A to support regulatory approval and commercialisation of its next-generation device, bringing total funding to nearly €28 million. In related preventive care sectors, Lucis secured €7.2 million in Seed funding to expand its biomarker-based health analytics platform across Europe while GlycanAge raised €7.4 million to scale its glycan-based diagnostics for preventive ageing care.

Combined these 2025 funding rounds demonstrate a strong investment climate, with roughly €31 million allocated to startups delivering continuous monitoring, personalized metabolic insights and preventive diagnostics complementing innovations like Liom’s non-invasive glucose monitoring wearable.

“Our miniaturisation breakthrough significantly increases light throughput versus current state-of-the-art solutions even outperforming table-sized lab-scale devices by 12x – and with that unlocks prior unseen performance, a >24h battery life, smartwatch sizing and manufacturability at scale” Grünstein adds.

Founded in 2017 by Leo Grünstein, Liom Health (formerly Spiden) is a Swiss HealthTech startup advancing preventive and personalized health monitoring through a novel wearable that provides real-time biophysical feedback.

Liom’s first product, expected in 2028, is a non-invasive glucose-monitoring wearable offering a comprehensive view of metabolic health. The company recently achieved a breakthrough by miniaturizing its proprietary Raman spectroscopy platform, demonstrating calibration-free, needle-free glucose measurement on over 130 subjects making it the world’s only non-invasive, calibration-free solution of its kind.

Liom also welcomed Marc Maurer, former co-CEO of On Running (valued at €11.8 billion/CHF 11 billion), as investor and Board member. Marc brings expertise in product strategy, consumer value creation, branding, and marketing, particularly at the intersection of health, fitness, and consumer products, supporting Liom’s transition from R&D to product development and commercialisation.

Maurer states: “Nutrition and movement are absolutely key to a high quality of life. Having access to glucose measurements through a wearable on your wrist, without the need for a needle, will allow all of us to understand the impact of nutrition and movement on our body much better and therefore live a healthier life. Liom unlocks mass-adoption by consumers & athletes vs current microneedle CGM devices.

“I believe Liom has the potential to disrupt and significantly expand the wearable market that has been created by Apple Watch, Samsung Galaxy Watch, Fitbit, Garmin, Whoop, Oura, etc – yet hasn’t seen sensor-level innovation over the past decade.”